Diabetes External Innovation
Indianapolis Indiana UNITED STATES
Brian has been at Eli Lilly since April 2006 where his role within the Diabetes External Innovation group is to lead the evaluation of external partnering opportunities in diabetes for technical merit and portfolio fit, in which capacity he has reviewed hundreds of programs and been a key player in the signing of multiple deals. Prior to coming to Lilly, he spent 11 years in the Metabolic Disorders group at Bayer Pharmaceuticals where his laboratory was engaged in obesity drug discovery and he held multiple leadership positions in the management of the Obesity Research portfolio. Brian completed his post-doctoral studies at The Johns Hopkins University School of Medicine, where he studied dopaminergic signaling, following his graduate studies at Purdue University where he investigated Drosophila photoreceptor signal transduction and his thesis was awarded the first A.H. Ismail Interdisciplinary Dissertation Award. Dr. Bloomquist has been a speaker or panelist at multiple conferences including Bio-Europe, Biotech Showcase, GTC Bio, Mass Bio, Ausbiotech, the Translational Research Institute, and the Queensland Investment Forum, has been cited multiple times in Close Concerns, a leading diabetes and obesity healthcare information company, is an inventor on a number of patents, and is the author of multiple peer-reviewed publications, including an article highlighted on the cover of the journal Cell.
None yet.